Log in with your email address username.


[Correspondence] Severe asthma and asthma-chronic obstructive pulmonary disease syndrome – Authors’ reply

We thank Yang Xia and colleagues for their interest in the recently published finding1 that dupilumab added to medium-dose to high-dose inhaled corticosteroids plus a long-acting β2-agonist in adults with uncontrolled persistent asthma improved lung function, reduced severe exacerbation rates, improved quality-of-life measures, and was generally well tolerated. Xia and colleagues suggested that some patients in the pivotal asthma phase 2b study met criteria for asthma-chronic obstructive pulmonary disease overlap syndrome and that these patients could also benefit from dupilumab treatment.